Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S, Reusch U, Knackmuss S, Kluge M, Damrat M, Pahl J, Schniegler-Mattox U, Mueller T, Fucek I, Ellwanger K, Tesar M, Haneke T, Koch J, Treder M, Fischer W, Rajkovic E.
Wingert S, et al. Among authors: tesar m.
MAbs. 2021 Jan-Dec;13(1):1950264. doi: 10.1080/19420862.2021.1950264.
MAbs. 2021.
PMID: 34325617
Free PMC article.